By Adriano Marchese
Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval.
The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food and Drug Administration approved the new drug application for Gozellix.
Gozellix helps with advanced imaging for prostate cancer, making it easier to detect. It provides a longer shelf life and an extended distribution radius compared to existing gallium-based imaging products, Telix said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 21, 2025 06:58 ET (10:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。